Background
Phase III RCT. 151 patients with newly diagnosed metastatic NSCLC. Randomized to early palliative care (PC) integrated with standard oncologic care vs standard oncologic care alone. PC involved regular meetings with palliative care team from time of diagnosis. Primary aim: assess whether early PC improves quality of life and potentially survival.
Interventions and follow up
Arm A: Early palliative care: outpatient PC team visits within 3 weeks of enrollment + standard oncologic therapy
Arm B: Standard oncologic care alone (PC on request only)
Primary endpoint: QoL (FACT-L total score at 12 weeks)
mFollow up: 12 weeks (QoL primary); OS follow-up continued
Arm B: Standard oncologic care alone (PC on request only)
Primary endpoint: QoL (FACT-L total score at 12 weeks)
mFollow up: 12 weeks (QoL primary); OS follow-up continued
Results
FACT-L at 12 wks (early PC): Mean 98.0 vs standard 91.5, P=.03
mOS (early PC): 11.6 months vs standard 8.9 months, P=.02 — survival benefit
Aggressive end-of-life care (early PC): Less chemotherapy in last 60 days (33% vs 54%), more hospice use
mOS (early PC): 11.6 months vs standard 8.9 months, P=.02 — survival benefit
Aggressive end-of-life care (early PC): Less chemotherapy in last 60 days (33% vs 54%), more hospice use
Adverse events
Main adverse events: N/A — this is a supportive care trial. Early PC was well-tolerated; no adverse events from the intervention itself. Less aggressive end-of-life care in the PC arm reduced treatment-related morbidity.
Conclusions
Early palliative care integration from diagnosis improved QoL, reduced depressive symptoms, and was associated with longer survival in metastatic NSCLC compared to standard care. Patients receiving early PC had less aggressive end-of-life care and more time in hospice. This landmark trial changed oncology practice globally.
Key Limitations
Key Limitations: Single institution (MGH). Unblinded. Small sample size. The OS benefit (~2.7 months) in a supportive care intervention requires careful interpretation — likely mediated by better PS maintenance and less toxic late-line therapy. May not generalize across health systems and cultures.
Clinical Context
Temel 2010 transformed the paradigm of oncology care: early PC integration is now endorsed by ASCO, NCCN, and ESMO as standard of care for patients with metastatic cancer. It fundamentally shaped how RT oncologists approach symptom-oriented treatment planning alongside curative-intent therapy for advanced disease.
References